Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 4
1950 7
1951 6
1952 6
1953 2
1954 2
1955 2
1956 1
1959 1
1960 1
1964 4
1966 1
1967 1
1969 1
1970 2
1972 1
1975 1
1976 2
1977 1
1984 1
1985 2
1986 3
1987 5
1991 1
1994 2
1995 1
1997 1
1998 4
1999 2
2000 11
2001 11
2002 8
2003 17
2004 8
2005 8
2006 14
2007 8
2008 4
2009 5
2010 5
2011 3
2012 5
2013 1
2014 1
2015 4
2016 5
2017 6
2018 6
2019 9
2020 13
2021 18
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Yusuf S, et al. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27040132 Free article. Clinical Trial.
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Subbiah V, et al. Among authors: longhi a. Clin Cancer Res. 2022 Jul 1;28(13):2762-2770. doi: 10.1158/1078-0432.CCR-22-0696. Clin Cancer Res. 2022. PMID: 35486638 Free PMC article. Clinical Trial.
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N, Venkatramani R, Hecker-Nolting S, Melcon SG, Locatelli F, Bautista F, Longhi A, Lervat C, Entz-Werle N, Casanova M, Aerts I, Strauss SJ, Thebaud E, Morland B, Nieto AC, Marec-Berard P, Gambart M, Rossig C, Okpara CE, He C, Dutta L, Campbell-Hewson Q. Gaspar N, et al. Among authors: longhi a. Lancet Oncol. 2021 Sep;22(9):1312-1321. doi: 10.1016/S1470-2045(21)00387-9. Epub 2021 Aug 17. Lancet Oncol. 2021. PMID: 34416158 Clinical Trial.
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?
Palmerini E, Torricelli E, Cascinu S, Pierini M, De Paolis M, Donati D, Cesari M, Longhi A, Abate M, Paioli A, Setola E, Ferrari S. Palmerini E, et al. Among authors: longhi a. Pediatr Blood Cancer. 2019 Aug;66(8):e27792. doi: 10.1002/pbc.27792. Epub 2019 May 6. Pediatr Blood Cancer. 2019. PMID: 31058424
Periosteal osteosarcoma: a single-institution experience.
Cesari M, Alberghini M, Vanel D, Palmerini E, Staals EL, Longhi A, Abate M, Ferrari C, Balladelli A, Ferrari S. Cesari M, et al. Among authors: longhi a. Cancer. 2011 Apr 15;117(8):1731-5. doi: 10.1002/cncr.25718. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472720 Free article.
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Stanic J, Mellone M, Napolitano F, Racca C, Zianni E, Minocci D, Ghiglieri V, Thiolat ML, Li Q, Longhi A, De Rosa A, Picconi B, Bezard E, Calabresi P, Di Luca M, Usiello A, Gardoni F. Stanic J, et al. Among authors: longhi a. Neurobiol Dis. 2017 Dec;108:54-64. doi: 10.1016/j.nbd.2017.08.001. Epub 2017 Aug 18. Neurobiol Dis. 2017. PMID: 28823933 Free article.
Palliative therapy for osteosarcoma.
Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, Bacci G, Mercuri M. Errani C, et al. Among authors: longhi a. Expert Rev Anticancer Ther. 2011 Feb;11(2):217-27. doi: 10.1586/era.10.172. Expert Rev Anticancer Ther. 2011. PMID: 21342041 Review.
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050).
Gaspar N, Campbell-Hewson Q, Gallego Melcon S, Locatelli F, Venkatramani R, Hecker-Nolting S, Gambart M, Bautista F, Thebaud E, Aerts I, Morland B, Rossig C, Canete Nieto A, Longhi A, Lervat C, Entz-Werle N, Strauss SJ, Marec-Berard P, Okpara CE, He C, Dutta L, Casanova M. Gaspar N, et al. Among authors: longhi a. ESMO Open. 2021 Oct;6(5):100250. doi: 10.1016/j.esmoop.2021.100250. Epub 2021 Sep 22. ESMO Open. 2021. PMID: 34562750 Free PMC article. Clinical Trial.
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.
Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E. Boye K, et al. Among authors: longhi a. Cancer Immunol Immunother. 2021 Sep;70(9):2617-2624. doi: 10.1007/s00262-021-02876-w. Epub 2021 Feb 12. Cancer Immunol Immunother. 2021. PMID: 33580363 Free PMC article. Clinical Trial.
240 results